Does apolipoprotein E influence learning and memory in the nondemented oldest old?
A Salo1, R Ylikoski, A Verkkoniemi
1Kauniala Hospital, Kauniainen, Finland. poliklinikka@kauniala.fi
International Psychogeriatrics
|May 11, 2002
Summary
This study found no link between apolipoprotein E (apoE) alleles and cognitive function in the oldest adults. ApoE-epsilon4 and apoE-epsilon2 alleles did not affect learning and memory in nondemented individuals aged 85 and over.
Area of Science:
- Neuroscience
- Genetics
- Gerontology
Background:
- The apolipoprotein E (apoE) gene, particularly the epsilon4 allele, is linked to increased risk of Alzheimer's disease and cognitive decline.
- The apoE-epsilon2 allele has been suggested to have a protective effect against cognitive impairment.
- Investigating these associations in the oldest-old population (85+ years) is crucial for understanding late-life cognition.
Purpose of the Study:
- To examine the relationship between apolipoprotein E (apoE) epsilon4 and epsilon2 alleles and cognitive performance in nondemented individuals aged 85 years and older.
- To determine if specific apoE genotypes are associated with differences in learning, memory, verbal fluency, or conceptualization in the very elderly.
Main Methods:
- Study included 46 nondemented individuals aged 85+ from Vantaa, Finland.
- ApoE genotyping was performed using the minisequencing technique.
- Cognitive functions were assessed using the Fuld Object-Memory Evaluation, verbal fluency tests, and the Similarities subtest of the WAIS-R.
Main Results:
- No statistically significant differences in learning, memory, verbal fluency, or conceptualization were found between apoE-epsilon4 carriers and noncarriers.
- Similarly, no significant differences were observed when comparing apoE-epsilon2 carriers to noncarriers.
- The study failed to support the hypotheses linking apoE-epsilon4 to poorer and apoE-epsilon2 to better cognitive performance in this age group.
Conclusions:
- Apolipoprotein E (apoE) alleles do not appear to have a detectable relationship with learning and memory in nondemented very elderly individuals.
- These findings suggest that other genetic or environmental factors may play a more significant role in cognitive function in the oldest-old population.
- Further research is needed to fully elucidate the role of apoE in cognitive aging, especially in centenarian and supercentenarian populations.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...